SMTI Key Statistics, Chart & Performance
The current stock price of SMTI is 23.63 USD. In the past month the price decreased by -16.09%. In the past year, price decreased by -31.8%.
SMTI Latest News, Press Relases and Analysis
SMTI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| COO | COOPER COS INC/THE | 19.01 | 15.61B | ||
| SOLV | SOLVENTUM CORP | 13.49 | 13.90B | ||
| ALGN | ALIGN TECHNOLOGY INC | 16.44 | 11.41B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 22.42 | 4.94B | ||
| LNTH | LANTHEUS HOLDINGS INC | 10.21 | 4.04B | ||
| HAE | HAEMONETICS CORP/MASS | 17.47 | 3.92B | ||
| ICUI | ICU MEDICAL INC | 17.9 | 3.52B | ||
| XRAY | DENTSPLY SIRONA INC | 7.03 | 2.22B | ||
| UFPT | UFP TECHNOLOGIES INC | 24.34 | 1.62B | ||
| NEOG | NEOGEN CORP | 21.33 | 1.39B | ||
| STAA | STAAR SURGICAL CO | N/A | 1.26B | ||
| EMBC | EMBECTA CORP | 3.74 | 650.05M |
Related stock screener links
About SMTI
Company Profile
Sanara MedTech, Inc. engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. The company is headquartered in Fort Worth, Texas and currently employs 141 full-time employees. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. The company markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.
Company Info
SANARA MEDTECH INC
1200 Summit Avenue, Suite 414
Fort Worth TEXAS 76102 US
CEO: Ronald T. Nixon
Employees: 141
Phone: 18175292300
SANARA MEDTECH INC / SMTI FAQ
What does SANARA MEDTECH INC do?
Sanara MedTech, Inc. engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. The company is headquartered in Fort Worth, Texas and currently employs 141 full-time employees. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. The company markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.
What is the current price of SMTI stock?
The current stock price of SMTI is 23.63 USD. The price increased by 8.59% in the last trading session.
Does SANARA MEDTECH INC pay dividends?
SMTI does not pay a dividend.
What is the ChartMill technical and fundamental rating of SMTI stock?
SMTI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of SMTI stock?
SANARA MEDTECH INC (SMTI) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
Can you provide the PE ratio for SMTI stock?
SANARA MEDTECH INC (SMTI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.73).
Who owns SANARA MEDTECH INC?
You can find the ownership structure of SANARA MEDTECH INC (SMTI) on the Ownership tab.
SMTI Technical Analysis
SMTI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SMTI. SMTI has a bad profitability rating. Also its financial health evaluation is rather negative.
SMTI Financial Highlights
Over the last trailing twelve months SMTI reported a non-GAAP Earnings per Share(EPS) of -0.73. The EPS increased by 26.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -52.74% | ||
| ROE | -609.72% | ||
| Debt/Equity | 7.33 |
SMTI Forecast & Estimates
8 analysts have analysed SMTI and the average price target is 41.82 USD. This implies a price increase of 76.98% is expected in the next year compared to the current price of 23.63.
For the next year, analysts expect an EPS growth of 117% and a revenue growth 19.89% for SMTI